Cargando…
EMBR-01. CLASS I HDAC INHIBITORS AND PLK1 INHIBITORS SYNERGIZE IN MYC-AMPLIFIED MEDULLOBLASTOMA
BACKGROUND: Medulloblastoma (MB) is one of the most common malignant pediatric CNS tumors. Patients with Group 3 MBs harboring MYC amplification exhibit low survival rates. Surviving patients suffer from therapy-induced sequelae, which calls for new targeted therapy strategies. We and others have pr...
Autores principales: | Valinciute, Gintvile, Ecker, Jonas, Selt, Florian, Hielscher, Thomas, Schmidt, Christin, Sigaud, Romain, Ridinger, Johannes, Gatzweiler, Charlotte, Picard, Daniel, Oppermann, Sina, Blattner-Johnson, Mirjam, Jones, David T W, Oehme, Ina, Kool, Marcel, Remke, Marc, Pfister, Stefan M, Witt, Olaf, Milde, Till |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168241/ http://dx.doi.org/10.1093/neuonc/noab090.019 |
Ejemplares similares
-
Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells
por: Valinciute, Gintvile, et al.
Publicado: (2023) -
MBRS-19. SYNERGISM OF HDAC AND PARP INHIBITORS IN MYC-DRIVEN GROUP 3 MEDULLOBLASTOMA CELLS
por: Vollmer, Johanna, et al.
Publicado: (2020) -
EMBR-13. NOVEL SYNERGISTIC APPROACHES FOR TARGETED THERAPY OF MYC-DRIVEN MEDULLOBLASTOMA USING CRISPR/CAS9 GENE EDITING
por: Qin, Nan, et al.
Publicado: (2021) -
EMBR-18. LASER INTERSTITIAL THERMAL THERAPY FOR RECURRENT MEDULLOBLASTOMA
por: Xu, Jordan, et al.
Publicado: (2021) -
EMBR-19. SHH-DRIVEN MEDULLOBLASTOMA WITH CONCURRENT UNILATERAL RENAL AGENESIS
por: Aaroe, Ashley, et al.
Publicado: (2021)